Poppers and health: what is documented, and what is not

Last updated 3 September 202622 min read

Used the way it is meant to be, that is inhaled, never mixed with anything and never swallowed, poppers produces brief effects: a rush of warmth, dizziness, sometimes a headache, all of which pass within minutes. Serious accidents do happen and they are rare: almost all of them come down to three situations that can be named in one sentence. This page names them, with its sources, and also says what nobody yet knows.

Is poppers dangerous? The short answer

The short answer first. When inhaled at the usual doses, the toxicity of poppers is considered low: that is the wording used by the Conseil d’État, France’s highest administrative court, in 2013, on the evidence in the public-health file. What you are most likely to get is a headache or a few minutes of dizziness. That is not an accident, it is the expected result of a brief drop in blood pressure.

The long answer rests on one distinction, and that distinction is what makes the subject so confused everywhere else: the product is not dangerous in itself, it becomes dangerous in a small number of specific situations. The public data show this clearly. In the French poison-control centres’ survey covering January 2018 to April 2024, half of all exposures were accidental and seven cases in ten involved a route other than inhalation alone: swallowed, splashed on skin or in the eyes, or combined with something else. What sends someone to hospital is therefore almost never the use the product is sold for.

The three things never to do

If you only remember three lines from this page, make it these. They cover almost every serious accident recorded in France.

1. Never swallow itPoppers is inhaled, it is not drunk. Swallowing it, even a small amount, causes severe and sometimes fatal poisoning. It is the leading cause of serious accidents, and it is often accidental: a bottle knocked over next to a glass, a bottle left within a child’s reach. Close it and put it away after use.
2. Never combine it with an erectile-dysfunction drug or a nitrateViagra, Cialis and Levitra, but also glyceryl trinitrate, nicorandil and molsidomine: these medicines act on the same pathway as poppers, and combining them drops blood pressure far enough to cause collapse. This is the best-established risk in the whole file, and it is written in the official product information. The published cardiology guidance is 24h after sildenafil or vardenafil, 48h after tadalafil.
3. Never let the liquid touch skin, lips or eyesThe liquid burns on contact. A splash in the eye is an emergency: rinse thoroughly with water and call a poison-control centre. That is also why the bottle is kept upright and closed between uses.

What about deaths? There have been some, and we would rather say so than leave the question hanging. French poison-control centres recorded eight between January 2018 and April 2024, out of 1 406 reported cases. In the files where the circumstances are known, every one involved use alongside other substances; on the wider count in the addiction-monitoring report, poppers was the only substance involved in 2 cases out of 30. Set against roughly a million people who say they use it each year in France, that is rare, and it is concentrated on the three situations above. The detailed figures, with their periods and sources, are further down in the “going further” section.

Poppers side effects, and how long they last

These are the effects the vast majority of users get. They are not accidents: they are the expected consequences of a brief drop in blood pressure, and they clear on their own within minutes.

• Headache. The most common one, and a recognised medical entity: “headache attributed to use of a nitric oxide donor”, code 8.1.1 of the International Classification of Headache Disorders. The immediate form resolves within the hour after exposure ends: that is the only objective published timing on the subject. A delayed form, appearing between 2 and 12 hours and clearing within 72 hours, is described only in people who already have a primary headache disorder, migraine in particular. The guidance published by Drogues Info Service, the French public drug-information service, comes down to two steps: stop inhaling, go and breathe fresh air. No reliable source recommends medication for it.
• Dizziness and a faster heartbeat. An expected and short-lived pharmacological effect. The real risk is not the symptom, it is the fall: that is why the one constant recommendation from harm-reduction organisations is to be sitting or lying down.
• Irritation of the nose and lips. With repeated use this is well documented: a 2024 clinical review reports crusting around the nose in 72% of described cases and around the mouth in 56%. It usually clears on its own once use stops; a lesion that persists, spreads or becomes infected calls for a consultation. We cover burns and splashes separately, because liquid on the skin really does burn.
• What does not exist: the next-day hangover. It is documented nowhere: the comedown effects described in the literature occur within minutes, not the following morning.

How strong it feels varies from one bottle to another: it depends on the formula and the strength, two things we state on every product page in our catalogue. If you are still choosing between two bases, the comparison is in our page on the four formulas. And we devote a whole page to the common side effects, what triggers them and what makes them pass.

Contraindications: who should abstain or ask a doctor first

Beyond the three rules, some situations and some medical backgrounds call for medical advice before any use. The right-hand column says what we make of each one, and above all how well documented it is: they are not all documented to the same degree, and yet the trade quotes them all in the same tone.

The medical backgrounds quoted by the trade are not all documented to the same degree. This right-hand column is the one nobody publishes.

Two categories honestly have no answer: antidepressants, anxiolytics and stimulants, on which no data are published, not by the ANSM (the French medicines agency), nor by the pharmacological databases, nor by harm-reduction organisations; and an indirect trap affecting people on HIV treatment, where certain boosters multiply sildenafil exposure roughly tenfold. Absence of data does not mean absence of risk: that question goes to a doctor. The detail, background by background, is in our page on contraindications: heart, blood pressure, asthma, G6PD, pregnancy, and the substances are in combinations to avoid.

Poppers and feeling unwell: when to see a doctor, when to call 15

Five signs fall outside the ordinary effects and call for emergency help: a blue-grey colour of the lips, face or nails, slow or laboured breathing, chest pain, confusion, loss of consciousness. Call 15 or 112 without waiting to see whether it improves.

While waiting for help, four steps: stop inhaling and close the bottle, lay the person down with their legs raised, open the windows wide, stay with them and let them inhale nothing further. A single fainting episode after use, even with no consequences, warrants a consultation with an examination and an ECG. The full protocol, the numbers and what to tell the doctor are in our page on warning signs and emergency numbers.

Where to find help and independent information

We sell this product: we are not doctors, we are not a source of medical advice, and nothing above replaces a consultation. Here are the people who have nothing to sell you.

• Life-threatening emergency - loss of consciousness, laboured breathing, blue discolouration, chest pain: 15 or 112.
• Doubt, exposure, ingestion, a toxicology question: the French poison-control centres answer 24h a day. Ten centres cover France; their official directory is published on service-public.gouv.fr. Keep the bottle with you: its label and UFI code identify the exact formula.
• Questions about use, stopping, or support: Drogues Info Service, a service of Santé publique France, anonymous and free.
• Data and reviews: the OFDT, the French monitoring centre for drugs and addictive behaviours, publishes a regularly updated review of what is known about poppers, and the population surveys the figures on this page are drawn from.

If you are reading this page because you found a bottle belonging to your teenager, this is not the conversation to have: we have written the page for parents for that situation.

Want to go further? Let’s talk shop

Everything above is enough for informed use. What follows is for those who are genuinely interested in the subject: the mechanism of action, the real state of the literature, the public figures and what the French authorities make of them. It is more technical, deliberately so, and every claim points to its source.

How poppers works, in practice

The mechanism is known, published, and there is nothing mysterious about it. When inhaled, alkyl nitrites are partly metabolised and release nitric oxide (NO). That gas activates an enzyme, soluble guanylate cyclase, which raises cyclic GMP inside cells; intracellular calcium falls, and smooth muscle fibre relaxes. Blood vessels dilate, blood pressure drops briefly, and the heart speeds up to compensate. The foundational work on this pathway dates from 1981 and earned the 1998 Nobel Prize in Medicine.

Two consequences follow, and between them they explain more or less everything a user feels. Vasodilation produces the rush of warmth, the flushed face, the dizziness and the faster pulse. The relaxation of smooth muscle does not stop at blood vessels: it also affects the sphincters, which is what explains the sexual use of the product. It is exactly the same family of mechanisms that cardiology has exploited for over a century with nitrates.

Two false explanations need clearing up here, both of which circulate on retail sites: poppers does not “release serotonin, the happiness hormone” and does not “act on neural connections”. It is not a psychotropic in the usual sense, it is a very short-acting vasodilator. The effects appear within seconds and fade within minutes: the public sources do not agree on the number, the OFDT giving a euphoric effect of under two minutes and the ANSM an overall duration of 5 to 10 minutes, and no pharmacokinetic study settles it. The detail is in our page on how long the effect really lasts.

Why blue discolouration is the sign that matters

The blue-grey colour deserves an explanation, because it is the most specific sign and because almost nobody in this trade names it. It points to methaemoglobinaemia: nitric oxide oxidises the iron in haemoglobin, which then no longer carries oxygen properly. In a published series of 239 patients with methaemoglobinaemia, 25 cases, one in ten, were linked to poppers; the reported features were cyanosis (68%), reduced oxygen saturation (45%) and impaired consciousness (26%). It is treated in hospital, with methylene blue and oxygen, and it responds well when treated in time.

Long-term effects: what is poorly documented

A retailer has every interest in writing that “nothing is proven”. The trouble is that “nothing is proven” and “nothing has been looked for” are not the same sentence, and the reader deserves to know which case they are in. Here is the real state of knowledge, subject by subject.

• The brain and memory. No human study. The only signal available is in rodents, published in 2016, on learning, memory and coordination. That is a signal, not a demonstration, and we present it as such.
• Lungs and sinuses. Acute irritation is documented; no human study measures chronic damage. The 2025 addiction-monitoring opinion does flag newly identified respiratory complications, including severe lipoid and interstitial pneumonia, as an emerging signal.
• Fertility. No human data. The available animal literature concerns ingested nitrite salts, which does not transfer.
• Cancer. Isobutyl nitrite carries a harmonised European classification as a category 1B carcinogen under the CLP Regulation: that is what underpins its ban from sale to the general public across the European Union, and you will not find it here. Isopropyl nitrite, the dominant base on the market, has never been evaluated by the IARC: that means “not evaluated”, not “not carcinogenic”.
• The eyes. This is the best-documented long-term harm. A nitrite-related maculopathy was first described in 2010 by the team at the Quinze-Vingts hospital in Paris; the OFDT counts around ten cases of prolonged vision loss a year in France. We cover it in our page on eyesight.
• Latex condoms. A frequent question, and an honest answer: there is no literature on latex being degraded by direct contact with an alkyl nitrite. That is a genuine gap, not to be confused with oil-based lubricants, for which degradation is well established.
• Women. An almost total gap in the literature, and it has to be said plainly: research on poppers has been built almost entirely around men who have sex with men.

The public figures, and how to read them

They exist, they are public, and as far as we know no other French-speaking retailer publishes them. Here they are, with their periods and their sources, because a figure without a period means nothing.

Three public sources, three different scopes: the figures do not add up to one another.

Two readings are required at once, and giving only one would be dishonest. On one hand these cases are rare relative to how widespread the product is: according to the OFDT’s EROPP survey conducted in 2023 among 12 490 people, 14,9% of 18 to 64-year-olds say they have tried poppers and 3,8% have used it in the past year, which is on the order of a million people - against a little over a hundred reported cases a year. On the other hand these cases are increasing, and the tripling of reports between 2014 and 2023 is a fact, whatever share of it is down to rising use rather than rising accidents.

A word on what these figures do not say: a toxicovigilance system records what is reported to it, never the total number of incidents. They give orders of magnitude and trends, not prevalence. That cuts both ways.

Two official positions that do not contradict each other

The answer depends on the question asked, and that is precisely why the subject produces so many contradictory sentences. Two official characterisations coexist in France, and they do not conflict.

• The Conseil d’État, striking down the sales ban on 3 June 2013, found toxicity to be “low at the doses usually inhaled” and noted that no scientific study established a risk of dependence or abuse.
• The clinical toxicology literature, for its part, uses the word “moderate” (the journal Toxicologie Analytique et Clinique, 2023), with specific risks in chronic or diverted use, particularly by ingestion. The ANSM, for its part, publishes no adjective: its standing scientific committee came out on 27 June 2025 in favour of banning access for minors, after 324 addiction-monitoring cases in 36 months and 30 deaths between 2018 and 2024.

The first answers “what happens when it is inhaled normally?”, the second “what is seen in people who seek care or are admitted to hospital?”. Both are accurate. What nobody may write, on the other hand, is “safe” or “risk-free”: on a mixture classified as hazardous, the European CLP Regulation explicitly forbids statements that play down the danger, and those phrases are nonetheless everywhere in this trade.

There is finally a real and current disagreement, which we would rather show than hide. The Drogues Info Service factsheet still states that the product does not cause dependence. But the opinion issued on 27 June 2025 by the ANSM’s standing scientific committee, on the basis of the addiction-monitoring report quoted above, records 52 cases of substance-use disorder including 41 of dependence, and comes out in favour of banning access for minors. Two official positions, two dates, two methods: the reader is entitled to see the contradiction rather than read “no dependence”, as most retail sites still write. We cover dependence in a dedicated page.

Our sources, and the date they were last checked

This page was checked on 3 September 2026. Every health claim it contains points to a primary source: agency opinions and reports, published court decisions, medicine product information, peer-reviewed articles. Where the literature says nothing - long-term effects, fertility, latex, use by women - we write that, rather than filling the gap.

Two things will move and we will follow them: the addiction-monitoring survey reports announced for the first quarter of 2027, and whatever follows from the ANSM opinion of 27 June 2025 on access for minors. This page will be updated accordingly, with its date.